Scientists identify genetic variants that reduce cigarette addiction severity

Somewhere in the human genome, tucked among millions of genetic instructions, sits a small piece of code that determines whether a person will smoke a single cigarette after dinner or burn through a pack before lunch. Scientists have just identified what that code looks like, and the discovery is reshaping how we understand one of the world's most stubborn addictions.

Researchers from Aarhus University in Denmark and UCLA published findings this week in Nature Communications describing genetic variants in a gene called CHRNB3 that appear to act as a natural brake on cigarette consumption. The team sequenced the genomes of nearly 38,000 smokers drawn from a Mexican patient database that has been collecting health information since the 1990s. What they found was striking: people carrying certain variants of this gene smoked between 21 and 78 percent fewer cigarettes per day than those with the most common version. The variants were particularly prevalent among people of indigenous Mexican ancestry—a population that researchers note is often underrepresented in scientific studies. To validate their findings, the team examined similar patterns in approximately 130,000 people of European descent from the UK Biobank and 180,000 of East Asian descent from the Japanese Biobank. The pattern held across all three populations.

The discovery matters because it reframes a question that has haunted public health for decades: why can some people smoke casually, drifting in and out of the habit with little struggle, while others find themselves reaching for a cigarette compulsively, unable to stop despite knowing the cost? The answer, it turns out, is not purely psychological or a matter of willpower. Biology plays a role. Tobacco kills approximately 7 million people annually according to the World Health Organization, making it one of the leading risk factors for heart disease, respiratory illness, and more than twenty types of cancer. Yet millions continue to smoke, not because they lack discipline, but because nicotine—the active compound in tobacco—hijacks the brain's reward system with remarkable efficiency.

Here is how the mechanism works: the CHRNB3 gene contains instructions for building a protein called the beta-3 subunit of the nicotinic acetylcholine receptor. Nicotine acts like a key, fitting into this receptor and triggering a cascade of neurological effects that reinforce the desire to smoke. The researchers discovered that genetic variants in CHRNB3 produce slightly different versions of this receptor protein. When a person carries one of these variants, their brain responds to nicotine differently—less intensely, less compulsively. The result is that they naturally smoke less, not because they try harder, but because their biology offers them a small advantage.

Ella Campbell, a spokesperson for Regeneron, the biotechnology company involved in the research, explained the implications in an interview. The variants are inherited; people are born with them. Those who carry them have a version of the CHRNB3 protein that interacts with nicotine in a subtly different way, changing how their brain responds to the drug. "For many people, smoking a lot or a little is not simply a matter of willpower," Campbell said. "Some genuinely struggle against their own biology, which makes quitting tobacco much harder." She acknowledged that researchers still do not fully understand the biological mechanisms at work and that future studies will need to explore this further.

The findings open a pharmaceutical pathway forward. If genetic variants can naturally reduce smoking intensity, then drugs designed to mimic those variants might help people quit. Campbell noted that the approach mirrors how other medications were developed—for instance, cholesterol-lowering drugs called PCSK9 inhibitors were inspired by people born with natural loss-of-function variants. However, she cautioned that any treatment based on this discovery remains years away. The research is in an early phase, and moving from genetic insight to an approved medication requires extensive clinical testing.

One important caveat emerged from the data: the variants do not appear to prevent people from starting to smoke in the first place. When researchers compared people who had ever smoked with those who never had, they found no significant protective effect. In other words, carrying these variants does not make someone immune to becoming a smoker. But once someone does smoke, the variants seem to limit how much they smoke. The researchers also noted that they do not yet know whether people with these variants experience other health differences unrelated to smoking—a question they plan to investigate next.

The discovery does not excuse smoking, nor should it. Tobacco remains a choice with consequences, both for the person smoking and for those exposed to secondhand smoke. But it does offer something important: scientific validation that addiction is not simply a failure of character. For millions of people struggling to quit, the knowledge that their difficulty has roots in biology—not moral weakness—may itself be a form of hope.